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Abstract 
A mannitol derived 2,3-butanediacetal ethyl ketone displays high levels of 
diastereoselectivity in boron and titanium mediated aldol reactions with a range of aliphatic 
and aromatic aldehydes to afford syn aldol products in high yield. The stereochemical 
outcome of the reaction was determined using J-value analysis, NMR analysis of O-
acetylmandelate derivatives and X-ray crystallography.  
Introduction 
Since its discovery by Borodin,
1
 and independently by Wurtz,
2
 the aldol addition reaction has 
become one of the most important transformations in organic synthesis.
3
 Its ability to furnish 
-hydroxy carbonyl compounds with excellent levels of stereocontrol has led to its 
widespread employment in the total synthesis of natural products, particularly secondary 
metabolites derived from the polyketide biosynthetic pathway.
4
  
As part of our research exploring the synthetic utility of 2,3-butane-diacetal derivatives of 
polyol precursors,
5
 we have previously shown that a simple synthetic sequence can be used to 
convert D-mannitol (1), via the selectively functionalised intermediate 2 to either the 
equatorial (3) or axial (5) diastereoisomer of (5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-
dioxane-2-carbaldehyde at will (Scheme 1).
6
  
In many of the reactions in which they act as electrophiles, these aldehydes display excellent 
stereodirecting abilities, giving rise to a highly versatile stereochemical manifold.
7
 Building 
on this, we wished to explore the use of the 2,3-butane diacetal motif as the stereodirecting 
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group in a nucleophilic reaction partner and chose the aldol reaction as our initial subject of 
investigation. To this end, the equatorial ethyl ketone 4 was synthesised in high yield from 3 
using a simple Grignard-addition/Swern-oxidation sequence. In this manuscript, we report 
that boron and titanium mediated aldol reactions of 4 proceed with excellent levels of 
diastereoselectivity, furnishing syn,syn products with a range of aldehydes. 
 
Scheme 1 Reagents and conditions: i. EtMgBr, THF, -78 °C. ii. (COCl)2, Me2SO, Et3N, 
DCM, -78 °C. 
We began our investigation with benzaldehyde, 6a, as the electrophilic reaction partner. 
Initially exploring the generation of dialkyl boron enolates, a brief survey of reagents and 
conditions identified dicyclohexylboron chloride and triethylamine in diethyl ether at -60 °C 
as suitable, giving rise to high levels of stereocontrol whilst allowing the reaction to proceed 
at an acceptable rate.  
Under these conditions, using recently prepared dicyclohexyl boron chloride,
8
 the coupling of 
4 with benzaldehyde afforded a 98% yield of the product 7a in a diastereomeric ratio of 96:4 
as determined from 
1
H NMR spectroscopy (Scheme 2, Table 1). Using the same conditions, 4 
was then coupled with a series of aromatic and aliphatic aldehydes to afford the 
corresponding aldol products 7a-j in excellent yields and with very high levels of 
stereocontrol (Scheme 2, Table 1). An oxidative workup with alkaline hydrogen peroxide was 
used to convert the cyclohexyl groups on boron to cyclohexanol prior to chromatographic 
purification.  
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Scheme 2 Reagents and conditions:  4, cHex2BCl, Et3N, Et2O, -60 °C then 6a-j, Et2O -60 °C 
OR 4, TiCl4, iPr2NEt, CH2Cl2, -78 C, then 6a-c.  
 
Table 1 Results of the aldol coupling of 4. 
entry 6 Aldehyde Product Method
a 
3
JHH 4,5 
(Hz) 
Yield
b
 
(%) 
d.r. 
1 
6a 
 
7a 
B 4.6 98 96:4 
2 Ti '' 95 95:5 
3 
6b 
 
7b 
B 4.4 94 95:5 
4 Ti '' 92 94:6 
5 
6c  7c 
B 2.9 98 94:6 
6 Ti '' 91 94:6 
7 6d  7d B 3.6 92 95:5 
8 6e  7e B 3.1 97 97:3 
9 6f  7f B 3.2 96 94:6 
10 6g 
 
7g B 2.8 93 94:6 
11 6h 
 
7h B 3.5 94 95:5 
12 6i 
 
7i B 4.3 95 94:6 
13 6j  7j B 6.5 97 95:5 
a
 B = Boron, Ti = Titanium. 
b
 isolated yield after purification by column chromatography on 
silica gel.  
The relatively low - 1H-1H coupling constants (Table 1, 4th column) are consistent with the 
newly created stereocentres having a relative syn relationship, according to the Stiles–House  
model.
9
 Although dicyclohexylboron chloride often leads to the formation of E-boron 
enolates, the enolate geometry is highly dependent on the substitution pattern at the ' 
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position and related '-alkoxy ketones have been shown to afford exclusive formation of Z-
boron enolates using this reagent.
10
 
The absolute configuration of the  hydroxyl stereocentre in the aldol products was 
determined by comparison of the 
1
H NMR spectra of their (R)- and (S)-O-acetylmandelate 
esters (Scheme 3, example Δ(S-R) data are shown for compound 8d).  
 
Scheme 3 Reagents and conditions: (a) (R)-O-acetylmandelic acid, EDCI, DMAP, DCM, 0 
°C; (b) (S)-O-acetylmandelic acid, EDCI, DMAP, DCM, 0 °C. 
The stereochemical outcome of the reaction can be explained on the basis of a preferred 
enolate conformation in which the enolate C-O bond and the ' C-O bond are aligned in an 
antiperiplanar orientation for dipolar reasons. The approach of the aldehyde towards the least 
hindered face of the enolate in a Zimmerman–Traxler transition state then leads to the 
observed diastereoselectivity (Scheme 4).
3k, 11
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Scheme 4. Possible transition state model for the aldol addition. Dipoles shown in red.  
 
p-Bromobenzaldehyde 6b was specifically chosen in the hope that the p-bromobenzene ring 
might impart crystallinity to the corresponding product 7b. Pleasingly, this turned out to be 
the case and an X-ray crystal structure was obtained (Figure 1). In addition to providing 
further evidence for the relative syn-aldol stereochemistry, the presence of the heavy bromine 
atom also allowed the absolute stereochemistry to be determined from the X-ray data (which 
was in full agreement with the O-acetylmandelate analysis).  
 
Figure 1. X-ray structure of 7b. Thermal ellipsoids are shown at 50%.  
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In addition to the use of dicyclohexylboron chloride, we also briefly explored titanium 
reagents and found titanium tetrachloride to be equally competent in effecting these 
transformations (affording the same diastereomer of product) using diisopropylethylamine as 
the base and dichloromethane as the solvent (Table 1, entries 2,4,6). Conveniently, 
commercial grade material (purchased as a 1 M solution in dichloromethane) was found to be 
adequate, providing a possible advantage over the use of dicyclohexylboron chloride. As the 
titanium derived by-products are all easily hydrolysed and extracted into the aqueous phase 
on workup, this is also a potential advantage over the boron reagent (which leads to 
cyclohexyl byproducts whose removal generally necessitates additional workup steps). As the 
observed stereochemical outcome of the titanium mediated reaction was the same as the 
boron mediated aldol addition, it is also possible that the transition-state is similar to that 
shown in Scheme 4. Unlike the boron atom in dialkylboron enolates, the titanium metal in the 
enolate can bind to additional Lewis basic groups, such as the '-alkoxy group in 4. This 
might be expected to lead to the alternative syn aldol stereochemistry via an alternative 
enolate conformation. However, it is possible that the 2,3-butane-diacetal moiety (containing 
two adjacent quaternary carbons) would cause too much steric crowding to permit such a 
chelated structure (Figure 2). This might perhaps lead to a similar 'dipole aligned' 
Zimmerman-Traxler transition state as suggested for the boron mediated reaction.  
 
Figure 2. Potential steric crowding in hypothetical chelated titanium enolate conformations 
(left) and proposed favoured dipole-aligned enolate (right).  
Having established the efficacy of the aldol coupling, we wanted to establish that the 2,3-
butane-diacetal group could be removed in order to reveal the keto-diol functionality.  
Perhaps unsurprisingly, when this was attempted using trifluoroacetic acid (a reagent we have 
commonly used for this transformation), the reaction was also accompanied by a rapid retro-
aldol cleavage (Scheme 5). We also found that the retro-aldol cleavage of 7a was rapid at 
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room temperature using methanolic potassium carbonate, leading to the aldehyde and ketone 
in quantitative yield (Scheme 5). As yet, we have been unable to determine the order in which 
the butane-diacetal cleavage and retro-aldol processes occur under acidic conditions.  
 
Scheme 5. Retro-aldol cleavage transformations of 7a.  
To prevent the possibility of the retro-aldol process, we acylated the secondary alcohol in 7a. 
With this change, the butane-diacetal cleavage of the ester 10 was able to be performed in 
high yield (Scheme 6). We found that a THF-water solvent mixture, which provided a 
homogeneous reaction mixture after addition of TFA, led to the highest yield (95%) for this 
reaction.  
 
Scheme 6. Butane-diacetal cleavage and conversion to known hydroxy acid 13. 
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The keto-triol moiety in 11 could be cleaved to the carboxylic acid 12 in 93% yield using 
sodium periodate in MeCN-H2O-DCM. Saponification of the acetate group then afforded the 
well known hydroxy acid 13. Spectroscopic data and optical rotation values for this 
compound matched those provided in the literature,
12
 further confirming the 
diastereoselectivity of the aldol addition.  
Conclusion 
In conclusion, we have demonstrated that boron and titanium mediated aldol reactions of the 
mannitol derived 2,3-butane-diacetal ethyl ketone 4 proceed with high levels of substrate 
directed stereocontrol. The relative syn aldol stereochemistry was determined by analysis of 
the J-coupling values between the  and  hydrogens in the 1H NMR spectra. The absolute 
sense of stereocontrol was determined using X-ray crystallography, by NMR analysis of 
acetylmandelate derivatives and by conversion of aldol product 7a to the known hydroxy acid 
13.  We are currently investigating the use of this reaction in the synthesis of several 
polyketide natural products.  
Experimental Section 
General Experimental Details:  
 
Unless otherwise stated, reactions were performed using glassware that was dried by heating 
with a heat-gun under a flow of argon. Argon gas was pre-dried by passing through a 
cartridge of granular calcium chloride. Unless otherwise stated, all reagents were used as 
supplied from commercial sources without further purification. Dichloromethane used in 
reactions was purified using continuously recycling distillation over calcium hydride under a 
dry argon atmosphere. Tetrahydrofuran and diethyl ether used in reactions were pre-dried 
over freshly pressed sodium wire and then further purified using continuously recycling 
distillation over a mixture of calcium hydride and lithium aluminium hydride under a dry 
argon atmosphere using triphenylmethane as an indicator. Triethylamine and 
diisopropylethylamine were purified by distillation over calcium hydride and were stored 
over calcium hydride under an atmosphere of dry argon. Distilled water and aqueous 
solutions were prepared on site. Flash column chromatography was performed using Merck 
9385 grade silica gel purchased from Sigma-Aldrich. Analytical thin layer chromatography 
was performed using Merck Silica gel 60 F254 1 mm glass plates and visualised either by 
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ultraviolet radiation (254 nm) or by staining with potassium permanganate, cerium 
ammonium molybdate or vanillin solutions prepared by known procedures. 40/60 Petroleum 
ether refers to the distillate collected between 40–60 °C. 1H spectra were recorded on Bruker 
Avance 300 (300 MHz) or Bruker Avance DPX-400 (400 MHz) spectrometers. Chemical 
shifts are reported in parts per million (ppm) and the spectra are calibrated to the residual 
protic form of the deuterated solvent (7.26 ppm CDCl3; 3.31 ppm CD3OD). The multiplicity 
of a signal is reported as: s – singlet; d – doublet; t – triplet; br – broad; m – multiplet. 
Coupling constants (J) are given in hertz (Hz) to 1 decimal place. Apodisation functions 
(Gaussian, exponential, sine bell) were used to resolve multiplets in some cases. The centre 
of each peak is reported with the exception of unresolved multiplet signals where a range of 
ppm values are given. 
13
C NMR spectra were recorded on Bruker Avance 300 (75 MHz) or 
Bruker Avance DPX-400 (100 MHz) spectrometers with complete proton decoupling. 
Chemical shifts are reported in ppm and the spectra are calibrated to the deuterated solvent as 
the internal deuterium lock (77.00 ppm CDCl3; 49.00 ppm CD3OD). 
13
C signals are singlets 
unless otherwise stated and are reported to 2 decimal places. Infrared Spectroscopy was 
carried out using a thin film (evaporated from solution) on a Thermo Scientific Nicolet iS10 
ATR spectrometer. Mass Spectrometry was carried out on a Waters LCMS with electrospray 
ionisation and a QTOF analyser.  
 
Synthesis and Spectroscopic Data:  
 
1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)propan-1-one 4.  
 
Step 1) Grignard addition: To a stirring solution of the starting aldehyde 3 (10.0 g, 49.0 
mmol, 1.0 equiv) in dry tetrahydrofuran (300 mL) was added dropwise a solution of 
ethylmagnesium bromide (2.5 M in Et2O, 98.0 mL, 98.0 mmol, 2.0 equiv) at -78 C 
(acetone/dry-ice bath) under an atmosphere of dry argon. The reaction mixture was stirred at 
this temperature for 1 hr after which time it was quenched by the addition of saturated 
aqueous ammonium chloride (60 mL) followed by water (100 mL) and diethyl ether (200 
mL) with rapid stirring. The reaction mixture was allowed to warm to room temperature and 
the layers were separated. The aqueous layer was extracted thrice with diethyl ether (3 × 60 
mL) and the combined organic layers were washed with water (100 mL), brine (100 mL) and 
dried over magnesium sulfate. The solvent was removed under reduced pressure to afford a 
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crude material that was used in the next reaction without further purification or 
characterisation.  
Step 2) Swern oxidation: A solution of dimethyl sulfoxide (10.44 mL, 147 mmol, 3.0 equiv) 
in dichloromethane (200 mL) was added dropwise to a stirring solution of oxalyl chloride 
(6.30 mL, 73.5 mmol, 1.5 equiv) in dichloromethane (200 mL) at -78 C under an 
atmosphere of dry argon. The reaction was stirred at this temperature for 20 min. A solution 
of the crude material from the Grignard addition step in dichloromethane (200 mL) was 
added dropwise at -78 C. The reaction mixture was stirred at this temperature for 20 min. 
Triethylamine (40.9 mL, 294 mmol, 6.0 equiv) was added dropwise at -78 C. The reaction 
mixture was stirred at this temperature for 15 min before warming to -15 C (acetone/ice 
bath) and stirring for a further 45 min. The reaction was quenched by the addition of 
saturated aqueous ammonium chloride (100 mL) followed by diethyl ether (600 mL). The 
mixture was allowed to warm to room temperature and the layers were separated. The 
aqueous layer was extracted thrice with diethyl ether (3 × 100 mL). The combined organic 
layers were washed with saturated ammonium chloride solution (200 mL), water (200 mL) 
and brine (200 mL) before drying over magnesium sulfate. The solvent was removed under 
reduced pressure and to afford a crude product which was purified by column 
chromatography on silica gel (Merck 9385 grade) eluting with a gradient from 40/60 
petroleum ether to a 1:1 mixture of 40/60 petroleum ether to diethyl ether. After removal of 
solvent under reduced pressure, the product was isolated as a colourless oil (10.57 g, 93% 
over two steps).  
  
1
H NMR (400 MHz, CDCl3) δ 4.34 (dd, J = 10.5, 4.3 Hz, 1H), 3.73 (dd, J = 11.5, 4.3 Hz, 
1H), 3.68 (dd, J = 11.5, 10.5 Hz, 1H), 3.31 (s, 3H), 3.25 (s, 3H), 2.78 (dq, J = 18.8, 7.2 Hz, 
1H), 2.56 (dq, J = 18.8, 7.2 Hz, 1H), 1.35 (s, 3H), 1.28 (s, 3H), 1.03 (dd, J = 7.2, 7.2 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 209.3, 99.7, 98.1, 72.6, 59.7, 48.3, 48.1, 31.7, 17.7, 17.5, 6.7. 
FTIR (thin film) νmax cm
-1
 2990, 2946, 2833, 1716, 1459, 1405, 1374, 1258, 1212, 1165, 
1137, 1115, 1054, 1035, 1010, 987, 944, 878, 841, 773. HRMS (ESI-TOF, m/z) calculated 
for C11H20NaO5
+
 ([M+Na]
+
): 255.1203. Observed: 255.1213. 
 
 
 
General procedure for boron mediated aldol reactions:  
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Triethylamine (179 µL, mmol, 1.29  mmol, 3.0 equiv) was added dropwise to a solution of 
dicyclohexylboron chloride ( 188 µL, 0.862 mmol, 2.0 equiv) in dry diethyl ether (1 mL) at -
60 C (chloroform/dry-ice bath) under a dry argon atmosphere. After stirring at this 
temperature for 2 min, a solution of the starting ketone 4 (100 mg, 0.431 mmol, 1.0 equiv) in 
dry diethyl ether (1 mL) was added at -60 C. The mixture was stirred at this temperature for 
30 min, during which a significant amount of white precipitate was formed. To this 
suspension was added a solution of the aldehyde (1.94 mmol, 4.5 equiv) in dry diethyl ether 
(1 mL). The mixture was stirred at -60 C for 5 h. To the reaction mixture was added 
saturated aqueous ammonium chloride solution (2 mL) with rapid stirring followed by the 
addition of diethyl ether (10 mL). The mixture was allowed to warm to room temperature and 
the layers were separated. The aqueous layer was thrice extracted with diethyl ether (3 × 5 
mL) and the combined organic layers were dried over magnesium sulfate before removing 
the solvent under reduced pressure. The organic material was then dissolved in methanol (6 
mL) and pH 7 aqueous phosphate buffer (2 mL) was added to the resulting solution. Into this 
cloudy suspension was added aqueous hydrogen peroxide (2 mL, 30% wt/vol.) and the 
mixture was stirred rapidly at room temperature for 30 min. Diethyl ether (20 mL) and water 
(20 mL) were added and the mixture was stirred rapidly for 2 min. The layers were separated 
and the aqueous layer was extracted with diethyl ether (10 mL). The combined organic layers 
were washed with water (10 mL) before drying over magnesium sulfate. The solvent was 
removed under reduced pressure and the crude material was purified by column 
chromatography on silica gel (Merck 9385 grade), eluting with a solvent gradient from 40/60 
petroleum ether to a 1:1 mixture of 40/60 petroleum ether to diethyl ether.  
 
General procedure for titanium mediated aldol reactions:  
 
Diisopropylethylamine (85 µL, 0.517 mmol, 1.2 equiv) was added to a solution of the starting 
ketone 4 (100 mg, 0.431 mmol, 1.0 equiv) in dichloromethane (4 mL) at -78 C (acetone/dry-
ice bath) under a dry argon atmosphere. To this solution was added dropwise a solution of 
titanium tetrachloride in dichloromethane (1.0 M, 517 µL, 0.517 mmol, 1.2 equiv) at -78 C. 
The reaction mixture was stirred at this temperature for 2 min. A solution of the aldehyde 
(0.517 mmol, 1.2 equiv) in dichloromethane was added dropwise at -78 C. The reaction 
mixture was stirred at this temperature for 10 min. Saturated aqueous sodium bicarbonate (10 
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mL) was added dropwise with rapid stirring, followed by diethyl ether (10 mL). The mixture 
was allowed to warm to room temperature and extracted thrice with diethyl ether (3 × 10 
mL). The combined organic layers were washed with water (10 mL), brine (10 mL) and dried 
over magnesium sulfate. The solvent was removed under reduced pressure to afford the crude 
material which was purified was purified by column chromatography on silica gel (Merck 
9385 grade), eluting with a solvent gradient from 40/60 petroleum ether to a 1:1 mixture of 
40/60 petroleum ether to diethyl ether.  
 
(2S,3S)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-hydroxy-2-methyl-3-
phenylpropan-1-one 7a.  
 
(Boron aldol: 143 mg from 100 mg of 4, 98%. Titanium aldol: 139 mg from 100 mg of 4, 
95%) 
 
1
H NMR (400 MHz, CDCl3) δ 7.39 – 7.25 (m, 5H), 5.12 (dd, J = 4.6, 3.1 Hz, 1H), 4.32 (dd, 
J = 10.1, 4.8 Hz, 1H), 3.70 – 3.59 (m, 2H), 3.47 (qd, J = 7.0, 4.6 Hz, 1H), 3.29 (s, 3H), 3.25 
(s, 3H), 2.61 (d, J = 3.1 Hz, 1H), 1.38 (s, 3H), 1.29 (s, 3H), 1.12 (d, J = 7.0 Hz, 3H). 
13
C 
NMR (101 MHz, CDCl3) δ 212.0, 141.9, 128.3, 127.6, 126.0, 99.8, 98.0, 73.4, 72.4, 59.6, 
48.8, 48.5, 48.1, 17.7, 17.5, 10.1. FTIR (thin film) νmax cm
-1
 3484 (br), 2991, 2946, 2833, 
1710, 1493, 1453, 1374, 1336, 1212, 1137, 1112, 1053, 1034, 944, 876, 840, 765, 748. 
HRMS (ESI-TOF, m/z) calculated for C18H26NaO6
+
 ([M+Na]
+
): 361.1622. Observed: 
361.1626. 
 
(2S,3S)-3-(4-bromophenyl)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-
hydroxy-2-methylpropan-1-one 7b.  
 
(Boron aldol: 169 mg from 100 mg of 4, 94%. Titanium aldol: 165 mg from 100 mg of 4, 
92%). 
 
1
H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 5.06 (dd, J 
= 4.4, 2.9 Hz, 1H), 4.34 (dd, J = 10.5, 4.5 Hz, 1H), 3.70-3.60 (m, 2H), 3.37 (qd, J = 7.0, 4.4 
Hz, 1H), 3.26 (s, 3H), 3.23 (s, 3H), 2.73 (d, J = 2.9 Hz, 1H), 1.35 (s, 3H), 1.28 (s, 3H), 1.08 
(d, J = 7.0 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 212.1, 140.9, 131.4, 127.7, 121.4, 99.8, 
98.1, 72.7, 72.6, 59.6, 48.5, 48.5, 48.1, 17.7, 17.5, 9.8. FTIR (thin film) νmax cm
-1
 3470 (br), 
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2991, 2946, 2833, 1710, 1487, 1455, 1374, 1213, 1165, 1139, 1114, 1071, 1054, 1035, 1010, 
986, 944, 878, 829, 789. HRMS (ESI-TOF, m/z) calculated for C18H25BrKO6
+
 ([M+K]
+
): 
455.0466. Observed: 455.0472. 
 
 
(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-hydroxy-2,4-
dimethylpentan-1-one 7c.  
 
(Boron aldol: 143 mg from 100 mg of 4, 98%. Titanium aldol: 119 mg from 100 mg of 4, 
91%) 
 
1
H NMR (400 MHz, CDCl3) δ 4.49 (dd, J = 10.6, 4.4 Hz, 1H), 3.78 – 3.63 (m, 2H), 3.61 – 
3.54 (m, 1H), 3.38 (qd, J = 7.0, 2.9 Hz, 1H), 3.32 (s, 3H), 3.24 (s, 3H), 2.12 (d, J = 3.9 Hz, 
1H), 1.66 (m, 1H), 1.35 (s, 3H), 1.28 (s, 3H), 1.07 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 6.6 Hz, 
3H), 0.90 (d, J = 6.7 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 212.5, 99.8, 98.0, 76.4, 71.7, 
59.8, 48.6, 48.1, 43.7, 31.2, 19.2, 19.1, 17.7, 17.5, 8.1. FTIR (thin film) νmax cm
-1
 3516 (br), 
2957, 2874, 2834, 1709, 1459, 1374, 1332, 1262, 1213, 1140, 1115, 1037, 1013, 945, 878. 
HRMS (ESI-TOF, m/z) calculated for C15H28KO6
+
 ([M+K]
+
): 343.1517. Observed: 
343.1526. 
 
(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-hydroxy-2-
methylbutan-1-one 7d.  
 
(Boron aldol: 110 mg from 100 mg of 4, 92%).  
 
1
H NMR (400 MHz, CDCl3) δ 4.43 (dd, J = 10.3, 4.7 Hz, 1H), 4.10 (qd, J = 6.3, 3.6 Hz, 1H), 
3.75-3.60 (m, 2H), 3.30 (s, 3H), 3.24 (s, 3H), 3.13 (qd, J = 7.1, 3.6 Hz, 1H), 2.51 (br s, 1H), 
1.35 (s, 3H), 1.28 (s, 3H), 1.16 (d, J = 6.3 Hz, 3H), 1.12 (d, J = 7.1 Hz, 3H). 
13
C NMR (101 
MHz, CDCl3) δ 212.7, 99.8, 98.0, 72.5, 67.5, 59.7, 48.5, 48.1, 47.1, 20.1, 17.7, 17.5, 9.6. 
FTIR (thin film) νmax cm
-1
 3493 (br), 2972, 2947, 2834, 1707, 1454, 1374, 1331, 1281, 1212, 
1137, 1113, 1055, 1034, 1004, 944, 911, 877, 841. HRMS (ESI-TOF, m/z) calculated for 
C13H24NaO6
+
 ([M+Na]
+
): 299.1465. Observed: 299.1474. 
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(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-hydroxy-2-
methylheptan-1-one 7e.  
 
(Boron aldol: 133 mg from 100 mg of 4, 97%).  
 
1
H NMR (400 MHz, CDCl3) δ 4.46 (dd, J = 10.5, 4.5 Hz, 1H), 3.93 (s, 1H), 3.72 (dd, J = 
11.5, 4.5 Hz, 1H), 3.67 (dd, J = 11.5, 10.5 Hz, 1H), 3.31 (s, 3H), 3.24 (s, 3H), 3.17 (qd, J = 
7.1, 3.1 Hz, 1H), 2.31 (br s, 1H), 1.60-1.25 (m, 6H), 1.35 (s, 3H), 1.28 (s, 3H), 1.09 (d, J = 
7.1 Hz, 3H), 0.89 (t, J = 7.0 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 212.6, 99.8, 98.0, 72.2, 
71.1, 59.7, 48.5, 48.1, 46.0, 34.0, 28.2, 22.5, 17.7, 17.5, 14.0, 8.9. FTIR (thin film) νmax cm
-1
 
3509 (br), 2935, 2834, 1708, 1456, 1374, 1212, 1165, 1137, 1114, 1036, 1008, 969, 944, 877, 
842. HRMS (ESI-TOF, m/z) calculated for C16H30NaO6
+
 ([M+Na]
+
): 341.1935. Observed: 
341.1952. 
 
(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-hydroxy-2-
methylpentan-1-one 7f.  
 
(Boron aldol: 115 mg from 100 mg of 4, 92%). 
 
1
H NMR (400 MHz, CDCl3) δ 4.48 (dd, J = 10.3, 4.7 Hz, 1H), 3.86 (ddd, J = 8.2, 5.4, 3.1 
Hz, 1H), 3.77 – 3.66 (m, 2H), 3.31 (s, 3H), 3.24 (s, 3H), 3.25 – 3.19 (m, 1H), 1.60 – 1.40 (m, 
2H), 1.37 (s, 3H), 1.30 (s, 3H), 1.12 (d, J = 7.1 Hz, 3H), 0.98 (dd, J = 7.4, 7.4 Hz, 3H). 
13
C 
NMR (101 MHz, CDCl3) δ 212.5, 99.8, 98.0, 72.8, 72.2, 59.8, 48.5, 48.1, 45.7, 27.3, 17.7, 
17.5, 10.4, 9.0. FTIR (thin film) νmax cm
-1
 3516 (br), 2941, 2878, 2834, 1708, 1456, 1374, 
1331, 1212, 1138, 1114, 1035, 1003, 974, 945, 878, 842.  HRMS (ESI-TOF, m/z) calculated 
for C14H30NO6
+
 ([M+NH4]
+
): 308.2068. Observed: 308.2070. 
 
(2S,3R)-3-cyclohexyl-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-
hydroxy-2-methylpropan-1-one 7g.  
 
(Boron aldol: 138 mg from 100 mg of 4, 93%). 
 
1
H NMR (400 MHz, CDCl3) δ 4.49 (dd, J = 10.6, 4.4 Hz, 1H), 3.75 (dd, J = 11.5, 4.4 Hz, 
1H), 3.69 (dd, J = 11.5, 10.6 Hz, 1H), 3.66 (dd, J = 8.4, 2.8 Hz, 1H), 3.38 (qd, J = 7.0, 2.8 
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Hz, 1H), 3.33 (s, 3H), 3.25 (s, 3H), 2.10 – 2.01 (m, 2H), 1.80 – 1.71 (m, 2H), 1.70 – 1.56 (m, 
3H), 1.41 – 1.10 (m, 3H), 1.36 (s, 3H), 1.29 (s, 3H), 1.06 (d, J = 7.0 Hz, 3H), 1.01 – 0.89 (m, 
2H). 
13
C NMR (101 MHz, CDCl3) δ 212.6, 99.8, 98.0, 75.2, 71.7, 59.8, 48.6, 48.1, 43.3, 
40.6, 29.5, 29.2, 26.3, 26.0, 25.8, 17.7, 17.5, 8.2. FTIR (thin film) νmax cm
-1
 3517 (br), 2991, 
2925, 2851, 1709, 1449, 1374, 1212, 1141, 1115, 1057, 1038, 1011, 978, 945, 879. HRMS 
(ESI-TOF, m/z) calculated for C18H32NaO6
+
 ([M+Na]
+
): 367.2091. Observed: 367.2098. 
 
(2S,3R,E)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-hydroxy-2-
methyldodec-6-en-1-one 7h.  
 
(Boron aldol: 157 mg from 100 mg of 4, 94%). 
 
1
H NMR (400 MHz, CDCl3) δ 5.50 – 5.33 (m, 2H), 4.45 (dd, J = 10.2, 4.6 Hz, 1H), 3.94 
(ddd, J = 7.7, 3.5, 3.5 Hz, 1H), 3.76 – 3.61 (m, 2H), 3.31 (s, 3H), 3.24 (s, 3H), 3.17 (qd, J = 
7.1, 3.5 Hz, 1H), 2.33 (br s, 1H), 2.21 – 2.04 (m, 2H), 2.03-1.90 (m, 2H), 1.56 (m, 1H), 1.44 
(m, 1H), 1.38 – 1.18 (m, 6H), 1.35 (s, 3H), 1.28 (s, 3H), 1.11 (d, J = 7.1 Hz, 3H), 0.87 (t, J = 
6.7 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 212.4, 131.4, 129.2, 99.8, 98.0, 72.3, 70.8, 59.8, 
48.5, 48.1, 46.2, 34.2, 32.5, 31.4, 29.2, 29.1, 22.5, 17.7, 17.5, 14.0, 9.3. FTIR (thin film) νmax 
cm
-1
 3516 (br), 2990, 2925, 2872, 2854, 1708, 1456, 1373, 1212, 1165, 1139, 1115, 1056, 
1036, 968, 945, 878, 842. HRMS (ESI-TOF, m/z) calculated for C21H38NaO6
+
 ([M+Na]
+
): 
409.2561. Observed: 409.2568. 
 
(2S,3R,E)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-hydroxy-2-methyl-
5-phenylpent-4-en-1-one 7i.  
 
(Boron aldol: 149 mg from 100 mg of 4, 95%). 
 
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.23 (m, 5H), 6.65 (d, J = 15.9 Hz, 1H), 6.19 (dd, J = 
15.9, 6.1 Hz, 1H), 4.64 (m, 1H), 4.49 (dd, J = 10.5, 4.5 Hz, 1H), 3.76 (dd, J = 11.5, 4.5 Hz, 
1H), 3.71 (dd, J = 11.5, 10.5 Hz, 1H), 3.40 (qd, J = 7.0, 4.3 Hz, 1H), 3.33 (s, 3H), 3.26 (s, 
3H), 2.64 (s, 1H), 1.39 (s, 3H), 1.31 (s, 3H), 1.20 (d, J = 7.0 Hz, 3H). 
13
C NMR (101 MHz, 
CDCl3) δ 211.8, 136.5, 131.5, 128.9, 128.6, 127.8, 126.5, 99.9, 98.1, 72.8, 72.7, 59.7, 48.5, 
48.1, 46.8, 17.7, 17.5, 10.5. FTIR (thin film) νmax cm
-1
 3479 (br), 2991, 2945, 2833, 1709, 
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1494, 1449, 1374, 1332, 1212, 1139, 1114, 1054, 1034, 966, 944, 877, 841, 747. HRMS 
(ESI-TOF, m/z) calculated for C20H28NaO6
+
 ([M+Na]
+
): 387.1778. Observed: 387.1790. 
 
(2S,3R,E)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-hydroxy-2-
methyloct-4-en-1-one 7j.  
 
(Boron aldol: 138 mg from 100 mg of 4, 97%). 
 
1
H NMR (400 MHz, CDCl3) δ 6.01 (dt, J = 15.4, 6.8, 1H), 5.75 (dd, J = 15.4, 6.5 Hz, 1H), 
4.76 (dd, J = 10.5, 4.4 Hz, 1H), 4.70  (m, 1H), 4.05 (dd, J = 11.5, 4.3 Hz, 1H), 4.00 (dd, J = 
11.5, 10.5 Hz, 1H), 3.66 (s, 3H), 3.64 – 3.55 (m, 1H), 3.58 (s, 3H), 2.72 (s, 1H), 2.39 – 2.28 
(m, 2H), 1.77 – 1.70 (m, 2H), 1.69 (s, 3H), 1.62 (s, 3H), 1.43 (d, J = 7.0 Hz, 3H), 1.22 (t, J = 
7.3 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 211.7, 133.4, 129.4, 99.8, 98.0, 73.0, 72.5, 59.7, 
48.5, 48.1, 46.7, 34.3, 22.2, 17.7, 17.5, 13.6, 10.5. FTIR (thin film) νmax cm
-1
 3485 (br), 
2956, 2932, 2873, 2834, 1709, 1456, 1374, 1212, 1165, 1138, 1114, 1055, 1035, 968, 945, 
877, 841. HRMS (ESI-TOF, m/z) calculated for C17H34NO6
+
 ([M+NH4]
+
): 348.2381. 
Observed: 348.2396.  
 
General procedure for the formation of (R)- and (S)-acetylmandelates:  
 
A mixture of the starting hydroxy ketone (0.015 mmol, 1.0 equiv), the corresponding (R) or 
(S)-O-acetylmandelic acid (5.8 mg, 0.030 mmol, 2.0 equiv), N-(3-dimethylaminopropyl)-N'-
ethylcarbodiimide hydrochloride (5.8 mg, 0.030 mmol, 2.0 equiv) and N,N-4-
dimethylaminopyridine (3.7 mg, 0.030 mmol, 2.0 equiv) in dry dichloromethane (1 mL) was 
stirred at room temperature for 2 h. Diethyl ether (3 mL) and water (3 mL) were added and 
the mixture was stirred for 10 min. The layers were separated and the organic layer was 
washed with saturated aqueous sodium bicarbonate (1 mL), saturated aqueous ammonium 
chloride (1 mL) then dried over magnesium sulfate. The solvent was removed under reduced 
pressure to afford the product as a viscous colourless oil.  
 
(R)-(1S,2S)-3-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-3-oxo-1-
phenylpropyl 2-acetoxy-2-phenylacetate (R)-8a.  
 
(7.3 mg from 5.0 mg of 7a, 95%).  
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1
H NMR (400 MHz, CDCl3) δ 7.50 – 7.38 (m, 5H), 7.33 – 7.21 (m, 5H), 6.32 (d, J = 5.3 Hz, 
1H), 5.96 (s, 1H), 4.18 (dd, J = 10.6, 4.3 Hz, 1H), 3.59 – 3.43 (m, 3H), 3.26 (s, 3H), 3.20 (s, 
3H), 2.17 (s, 3H), 1.38 (s, 3H), 1.26 (s, 3H), 0.77 (d, J = 6.8 Hz, 3H). 
13
C NMR (101 MHz, 
CDCl3) δ 208.0, 170.2, 167.9, 138.3, 133.6, 129.3, 128.8, 128.5, 128.0, 127.6, 125.8, 99.9, 
98.0, 76.0, 74.5, 72.0, 59.5, 48.7, 48.0, 47.9, 20.6, 17.8, 17.6, 9.5. FTIR (thin film) νmax cm
-1
 
2991, 2947, 2834, 1745, 1716, 1497, 1455, 1373, 1227, 1168, 1141, 1114, 1053, 1036, 1011, 
973, 943, 878, 737, 698. HRMS (ESI-TOF, m/z) calculated for C28H34KO9
+
 ([M+K]
+
): 
553.1834. Observed: 553.1850. 
 
(S)-(1S,2S)-3-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-3-oxo-1-
phenylpropyl 2-acetoxy-2-phenylacetate (S)-8a.  
 
(7.3 mg from 7a, 96%).  
 
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.29 (m, 5H), 7.19 – 7.10 (m, 3H), 6.95 – 6.89 (m, 2H), 
6.30 (d, J = 6.2 Hz, 1H), 5.98 (s, 1H), 4.23 (dd, J = 10.9, 4.1 Hz, 1H), 3.65 – 3.58 (m, 2H), 
3.52 (dd, J = 11.4, 10.9 Hz, 1H), 3.23 (s, 3H), 3.21 (s, 3H), 2.18 (s, 3H), 1.38 (s, 3H), 1.26 (s, 
3H), 1.06 (d, J = 6.8 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 208.3, 170.0, 167.7, 138.1, 
133.5, 129.2, 128.7, 128.2, 127.9, 127.8, 125.9, 99.9, 98.0, 76.2, 74.3, 72.2, 59.5, 48.6, 48.0, 
47.9, 20.6, 17.8, 17.5, 10.6. FTIR (thin film) νmax cm
-1
 2991, 2947, 2834, 1747, 1717, 1497, 
1455, 1373, 1229, 1206, 1170, 1142, 1115, 1054, 1036, 973, 944, 879, 749, 699. HRMS 
(ESI-TOF, m/z) calculated for C28H34KO9
+
 ([M+K]
+
): 553.1834. Observed: 553.1855. 
 
(R)-(1S,2S)-1-(4-bromophenyl)-3-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-
2-methyl-3-oxopropyl 2-acetoxy-2-phenylacetate (R)-8b.  
 
(7.9 mg from 6.0 mg 7b, 93%). 
 
1
H NMR (400 MHz, CDCl3) δ 7.49 – 7.36 (m, 7H), 7.12 (d, J = 8.4 Hz, 2H), 6.25 (d, J = 5.4 
Hz, 1H), 5.91 (s, 1H), 4.16 (dd, J = 10.7, 4.2 Hz, 1H), 3.57 – 3.43 (m, 3H), 3.24 (s, 3H), 3.21 
(s, 3H), 2.17 (s, 3H), 1.37 (s, 3H), 1.26 (s, 3H), 0.78 (d, J = 6.8 Hz, 3H). 
13
C NMR (101 
MHz, CDCl3) δ 207.7, 170.3, 167.9, 137.4, 133.3, 131.7, 129.4, 128.8, 127.6, 127.5, 122.0, 
99.9, 98.0, 75.4, 74.6, 72.2, 59.5, 48.7, 48.1, 47.7, 20.6, 17.8, 17.6, 9.6. FTIR (thin film) νmax 
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cm
-1
 2990, 2947, 2834, 1744, 1716, 1620, 1489, 1455, 1373, 1228, 1207, 1167, 1141, 1114, 
1074, 1053, 1035, 1010, 974, 942, 878. HRMS (ESI-TOF, m/z) calculated for C28H33BrKO9
+
 
([M+K]
+
): 631.0940. Observed: 631.0954. 
 
(S)-(1S,2S)-1-(4-bromophenyl)-3-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-
2-methyl-3-oxopropyl 2-acetoxy-2-phenylacetate (S)-8b.  
 
(8.6 mg from 6.2 mg 7b, 97%). 
 
1
H NMR (400 MHz, CDCl3) δ 7.44 – 7.32 (m, 4H), 7.28 – 7.23 (m, 3H), 6.77 (d, J = 8.4 Hz, 
2H), 6.23 (d, J = 6.3 Hz, 1H), 5.95 (s, 1H), 4.25 (dd, J = 10.9, 4.0 Hz, 1H), 3.63 (dd, J = 11.5, 
4.0 Hz, 1H), 3.57 – 3.49 (m, 2H), 3.22 (s, 6H), 2.18 (s, 3H), 1.37 (s, 3H), 1.26 (s, 3H), 1.06 
(d, J = 6.8 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 208.1, 170.1, 167.7, 137.3, 133.4, 131.4, 
129.4, 128.8, 127.8, 127.7, 122.0, 99.9, 98.1, 75.6, 74.2, 72.4, 59.5, 48.6, 48.1, 47.8, 20.6, 
17.8, 17.5, 10.8. FTIR (thin film) νmax cm
-1
 2991, 2947, 2834, 1746, 1716, 1489, 1455, 1373, 
1229, 1205, 1168, 1141, 1114, 1083, 1073, 1054, 1035, 1010, 973, 942, 878. HRMS (ESI-
TOF, m/z) calculated for C28H33BrKO9
+
 ([M+K]
+
): 631.0940. Observed: 631.0957. 
 
(R)-(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2,4-dimethyl-1-
oxopentan-3-yl 2-acetoxy-2-phenylacetate (R)-8c.  
 
(6.8 mg from 4.8 mg 7c, 90%).  
 
1
H NMR (300 MHz, CDCl3) δ 7.41-7.39 (m, 5H), 5.83 (s, 1H), 5.20 (dd, J = 8.8, 3.1 Hz, 
1H), 4.49 (dd, J = 10.8, 4.3 Hz, 1H), 3.58 (dd, J = 11.5, 4.3 Hz, 1H), 3.49 (dd, J = 11.5, 10.8 
Hz, 1H), 3.44 – 3.38 (m, 4H), 3.20 (s, 3H), 2.18 (s, 3H), 1.97 – 1.81 (m, 1H), 1.33 (s, 3H), 
1.27 (s, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H), 0.69 (d, J = 6.9 Hz, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ 208.6, 170.4, 168.6, 133.5, 129.3, 128.7, 127.8, 99.8, 98.0, 78.8, 
74.5, 71.3, 59.7, 48.9, 48.1, 42.9, 30.3, 20.7, 19.1, 18.8, 17.8, 17.6, 7.7. FTIR (thin film) νmax 
cm
-1
 2964, 2947, 2878, 2834, 1742, 1716, 1497, 1456, 1372, 1329, 1231, 1209, 1140, 1177, 
1115, 1049, 1037, 1010, 971, 943, 879. HRMS (ESI-TOF, m/z) calculated for C25H36KO9
+
 
([M+K]
+
): 519.1991. Observed: 519.2003.  
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(S)-(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2,4-dimethyl-1-
oxopentan-3-yl 2-acetoxy-2-phenylacetate (S)-8c.  
 
(7.4 mg from 5.0 mg 7c, 94%). 
 
1
H NMR (300 MHz, CDCl3) δ 7.47 – 7.34 (m, 5H), 5.87 (s, 1H), 5.21 (dd, J = 7.6, 4.5 Hz, 
1H), 4.55 (dd, J = 10.9, 4.2 Hz, 1H), 3.74 (dd, J = 11.3, 4.2 Hz, 1H), 3.61 (dd, J = 11.3, 10.9 
Hz, 1H), 3.52 (qd, J = 6.9, 4.5 Hz, 1H), 3.41 (s, 3H), 3.24 (s, 3H), 2.18 (s, 3H), 1.72 (m, 1H), 
1.35 (s, 3H), 1.28 (s, 3H), 1.04 (d, J = 6.9 Hz, 3H), 0.76 (d, J = 6.8 Hz, 3H), 0.53 (d, J = 6.6 
Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 209.1, 170.0, 168.6, 134.0, 129.2, 128.7, 127.7, 99.8, 
98.0, 78.9, 74.3, 71.6, 59.8, 48.8, 48.1, 43.3, 30.2, 20.7, 19.1, 17.8, 17.7, 17.6, 9.3. FTIR 
(thin film) νmax cm
-1
 2963, 2878, 2834, 1745, 1716, 1497, 1456, 1373, 1332, 1231, 1210, 
1176, 1141, 1116, 1055, 1037, 1011, 968, 944, 879. HRMS (ESI-TOF, m/z) calculated for 
C25H36KO9
+
 ([M+K]
+
): 519.1991. Observed: 519.2008. 
 
(R)-(2R,3S)-4-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-methyl-4-
oxobutan-2-yl 2-acetoxy-2-phenylacetate (R)-8d.  
 
(7.6 mg from 5.1 mg 7d, 91%). 
 
1
H NMR (300 MHz, CDCl3) δ 7.44 – 7.36 (m, 5H), 5.80 (s, 1H), 5.41 (qd, J = 6.4, 4.7 Hz, 
1H), 4.30 (dd, J = 10.3, 4.6 Hz, 1H), 3.59 (dd, J = 11.3, 4.6 Hz, 1H), 3.53 (dd, J = 11.3, 10.3 
Hz, 1H), 3.31 (s, 3H), 3.21 (s, 3H), 3.23 – 3.13 (m, 1H), 2.18 (s, 3H), 1.32 (s, 3H), 1.29 (d, J 
= 6.4 Hz, 3H), 1.26 (s, 3H), 0.83 (d, J = 6.9 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 208.4, 
170.4, 168.3, 133.7, 129.3, 128.8, 127.6, 99.8, 98.0, 74.7, 71.8, 71.8, 59.7, 48.7, 48.0, 46.4, 
20.6, 18.3, 17.7, 17.6, 9.3. FTIR (thin film) νmax cm
-1
 2989, 2947, 2834, 1741, 1715, 1497, 
1455, 1373, 1324, 1264, 1229, 1210, 1177, 1138, 1114, 1082, 1054, 1032, 1003, 963, 943, 
878. HRMS (ESI-TOF, m/z) calculated for C23H32KO9
+
 ([M+K]
+
): 491.1678. Observed: 
491.1693. 
 
(S)-(2R,3S)-4-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-3-methyl-4-
oxobutan-2-yl 2-acetoxy-2-phenylacetate (S)-8d.  
 
(7.3 mg from 4.5 mg 7d, 99%). 
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1
H NMR (300 MHz, CDCl3) δ 7.45 – 7.35 (m, 5H), 5.80 (s, 1H), 5.42 (qd, J = 6.3, 5.3 Hz, 
1H), 4.44 (dd, J = 10.7, 4.2 Hz, 1H), 3.72 (dd, J = 11.5, 4.2 Hz, 1H), 3.64 (dd, J = 11.5, 10.7 
Hz, 1H), 3.35 – 3.25 (m, 4H), 3.24 (s, 3H), 2.18 (s, 3H), 1.34 (s, 3H), 1.28 (s, 3H), 1.11 (d, J 
= 3.2 Hz, 3H), 1.09 (d, J = 3.8 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 208.8, 170.2, 168.2, 
133.6, 129.2, 128.8, 127.5, 99.8, 98.0, 74.6, 72.0, 71.8, 59.7, 48.6, 48.1, 46.3, 20.6, 17.8, 
17.7, 17.6, 10.4. FTIR (thin film) νmax cm
-1
 2989, 2946, 2834, 1742, 1715, 1497, 1455, 1373, 
1327, 1264, 1229, 1209, 1177, 1138, 1113, 1082, 1053, 1032, 1003, 963, 943, 878. HRMS 
(ESI-TOF, m/z) calculated for C23H32KO9
+
 ([M+K]
+
): 491.1678. Observed: 491.1688.  
 
(R)-(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-1-
oxoheptan-3-yl 2-acetoxy-2-phenylacetate (R)-8e.  
 
(7.8 mg from 5.3 mg 7e, 94%). 
 
1
H NMR (300 MHz, CDCl3) δ 7.42 – 7.36 (m, 5H), 5.80 (s, 1H), 5.43 (ddd, J = 7.5, 6.4, 3.5 
Hz, 1H), 4.37 (dd, J = 10.6, 4.4 Hz, 1H), 3.59 (dd, J = 11.5, 4.4 Hz, 1H), 3.51 (dd, J = 11.5, 
10.6 Hz, 1H), 3.37 (s, 3H), 3.30 – 3.23 (m, 1H), 3.21 (s, 3H), 2.18 (s, 3H), 1.77 – 1.45 (m, 
2H), 1.33 – 1.20 (m, 4H), 1.32 (s, 3H), 1.26 (s, 3H), 0.88 (t, J = 6.9 Hz, 3H), 0.77 (d, J = 6.9 
Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 208.4, 173.5, 168.5, 133.7, 129.3, 128.7, 127.7, 
99.8, 98.0, 74.6, 74.5, 71.5, 59.7, 48.8, 48.1, 44.6, 32.0, 27.5, 22.2, 20.7, 17.7, 17.6, 13.9, 8.2. 
FTIR (thin film) νmax cm
-1
 2953, 2873, 2835, 1742, 1716, 1497, 1456, 1373, 1331, 1263, 
1230, 1208, 1176, 1139, 1115, 1083, 1037, 1005, 967, 944, 879. HRMS (ESI-TOF, m/z) 
calculated for C26H38KO9
+
 ([M+K]
+
): 533.2147. Observed: 533.2170.  
 
(S)-(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-1-
oxoheptan-3-yl 2-acetoxy-2-phenylacetate (S)-8e.  
 
(8.6 mg from 6.1 mg 7e, 92%). 
 
1
H NMR (300 MHz, CDCl3) δ 7.46 – 7.33 (m, 5H), 5.82 (s, 1H), 5.40 (ddd, J = 8.3, 5.0 Hz, 
1H), 4.50 (dd, J = 10.9, 4.2 Hz, 1H), 3.73 (dd, J = 11.5, 4.2 Hz, 1H), 3.62 (dd, J = 11.5, 10.9 
Hz, 1H), 3.36 (s, 3H), 3.34 – 3.29 (m, 1H), 3.24 (s, 3H), 2.17 (s, 3H), 1.51 – 1.23 (m, 2H), 
1.34 (s, 3H), 1.28 (s, 3H), 1.20 – 1.05 (m, 2H), 1.06 (d, J = 6.9 Hz, 3H), 0.97 – 0.87 (m, 2H), 
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0.70 (t, J = 7.3 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 208.9, 170.1, 168.6, 133.8, 129.2, 
128.7, 127.6, 99.8, 98.0, 74.5, 74.5, 71.8, 59.7, 48.7, 48.1, 45.1, 32.0, 27.1, 22.0, 20.7, 17.7, 
17.6, 13.7, 9.6. FTIR (thin film) νmax cm
-1
 2954, 2873, 2834, 1742, 1713, 1526, 1496, 1455, 
1373, 1332, 1230, 1208, 1176, 1140, 1115, 1083, 1037, 964, 944, 879. HRMS (ESI-TOF, 
m/z) calculated for C26H38KO9
+
 ([M+K]
+
): 533.2147. Observed: 533.2170.  
 
(R)-(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-1-
oxopentan-3-yl 2-acetoxy-2-phenylacetate (R)-8f.  
 
(6.3 mg from 4.2 mg 7f, 93%). 
 
1
H NMR (300 MHz, CDCl3) δ 7.44 – 7.36 (m, 5H), 5.81 (s, 1H), 5.35 (ddd, J = 7.3, 6.9, 3.7 
Hz, 1H), 4.38 (dd, J = 10.6, 4.5 Hz, 1H), 3.59 (dd, J = 11.5, 4.5 Hz, 1H), 3.52 (dd, J = 11.5, 
10.6 Hz, 1H), 3.37 (s, 3H), 3.33 – 3.23 (m, 1H), 3.21 (s, 3H), 2.18 (s, 3H), 1.78 – 1.52 (m, 
2H), 1.32 (s, 3H), 1.26 (s, 3H), 0.93 (t, J = 7.4 Hz, 3H), 0.76 (d, J = 6.9 Hz, 3H). 
13
C NMR 
(75 MHz, CDCl3) δ 208.5, 170.4, 168.5, 133.5, 129.3, 128.7, 127.7, 99.8, 98.0, 75.8, 74.6, 
71.4, 59.7, 48.8, 48.8, 44.2, 25.5, 20.7, 17.8, 17.6, 9.9, 8.1. FTIR (thin film) νmax cm
-1
 2946, 
2881, 2835, 1743, 1717, 1497, 1456, 1373, 1332, 1263, 1231, 1211, 1178, 1142, 1116, 1083, 
1055, 1038, 1003, 970, 946, 879. HRMS (ESI-TOF, m/z) calculated for C24H34KO9
+
 
([M+K]
+
): 505.1834. Observed: 505.1843.  
 
(S)-(2S,3R)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-1-
oxopentan-3-yl 2-acetoxy-2-phenylacetate (S)-8f.  
 
(7.3 mg from 4.8 mg 7f, 94%). 
 
1
H NMR (300 MHz, CDCl3) δ 7.46 – 7.34 (m, 5H), 5.82 (s, 1H), 5.34 (ddd, J = 7.4, 6.0, 4.6 
Hz, 1H), 4.50 (dd, J = 10.8, 4.2 Hz, 1H), 3.73 (dd, J = 11.5, 4.2 Hz, 1H), 3.62 (dd, J = 11.5, 
10.8 Hz, 1H), 3.41 – 3.33 (m, 1H), 3.36 (s, 3H), 3.24 (s, 3H), 2.17 (s, 3H), 1.53 – 1.41 (m, 
2H), 1.34 (s, 3H), 1.28 (s, 3H), 1.06 (d, J = 6.9 Hz, 3H), 0.63 (t, J = 7.4 Hz, 3H). 
13
C NMR 
(75 MHz, CDCl3) δ 208.9, 170.1, 168.6, 133.8, 129.2, 128.7, 127.6, 99.8, 98.0, 76.0, 74.5, 
71.7, 59.7, 48.7, 48.1, 44.5, 25.4, 20.7, 17.8, 17.6, 9.6, 9.4. FTIR (thin film) νmax cm
-1
 2945, 
2880, 2834, 1742, 1716, 1497, 1455, 1373, 1332, 1266, 1229, 1208, 1176, 1138, 1114, 1084, 
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1054, 1035, 1004, 969, 944, 878. HRMS (ESI-TOF, m/z) calculated for C24H34KO9
+
 
([M+K]
+
): 505.1834. Observed: 505.1848.  
 
(R)-(1R,2S)-1-cyclohexyl-3-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-
methyl-3-oxopropyl 2-acetoxy-2-phenylacetate (R)-8g.  
 
(7.6 mg from 5.2 mg 7g, 97%). 
 
1
H NMR (400 MHz, CDCl3) δ 7.42 – 7.36 (m, 5H), 5.85 (s, 1H), 5.27 (dd, J = 8.6, 3.1 Hz, 
1H), 4.48 (dd, J = 10.8, 4.2 Hz, 1H), 3.57 (dd, J = 11.3, 4.2 Hz, 1H), 3.49 (dd, J = 11.3, 10.8 
Hz, 1H), 3.44 – 3.38 (m, 1H), 3.43 (s, 3H), 3.20 (s, 3H), 2.17 (s, 3H), 1.82 – 1.62 (m, 5H), 
1.33 (s, 3H), 1.27 (s, 3H), 1.26 – 0.84 (m, 6H), 0.70 (d, J = 6.9 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 208.6, 170.3, 168.6, 133.7, 129.3, 128.6, 127.8, 99.8, 98.0, 77.9, 74.5, 71.3, 
59.7, 48.9, 48.1, 42.4, 39.6, 29.3, 29.1, 26.1, 25.9, 25.7, 20.7, 17.8, 17.6, 7.7. FTIR (thin 
film) νmax cm
-1
 2990, 2928, 2853, 1743, 1716, 1451, 1373, 1319, 1231, 1210, 1178, 1141, 
1115, 1082, 1054, 1038, 1008, 975, 943, 890. HRMS (ESI-TOF, m/z) calculated for 
C28H40KO9
+
 ([M+K]
+
): 559.2304. Observed: 559.2321.  
 
(S)-(1R,2S)-1-cyclohexyl-3-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-
methyl-3-oxopropyl 2-acetoxy-2-phenylacetate (S)-8g.  
 
(8.0 mg from 5.6 mg 7g, %). 
 
1
H NMR (400 MHz, CDCl3) δ 7.47 – 7.33 (m, 5H), 5.88 (s, 1H), 5.24 (dd, J = 7.1, 4.9 Hz, 
1H), 4.52 (dd, J = 10.9, 4.1 Hz, 1H), 3.72 (dd, J = 11.3, 4.1 Hz, 1H), 3.61 (dd, J = 11.3, 10.9 
Hz, 1H), 3.52 (qd, J = 6.9, 4.9 Hz, 1H), 3.40 (s, 3H), 3.24 (s, 3H), 2.17 (s, 3H), 1.64 – 1.46 
(m, 2H), 1.44 – 1.32 (m, 1H), 1.33 (s, 3H), 1.28 (s, 3H), 1.29 – 1.18 (m, 2H), 1.16 – 1.06 (m, 
2H), 1.04 (d, J = 6.9 Hz, 3H), 0.99 – 0.82 (m, 2H), 0.78 – 0.60 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 209.3, 169.9, 168.6, 134.1, 129.1, 128.6, 127.7, 99.8, 98.0, 78.1, 74.3, 71.78, 
59.8, 48.7, 48.1, 42.7, 39.6, 29.2, 27.8, 26.0, 25.8, 25.5, 20.7, 17.8, 17.6, 9.6. FTIR (thin 
film) νmax cm
-1
 2991, 2930, 2854, 1746, 1716, 1453, 1373, 1324, 1231, 1209, 1177, 1141, 
1116, 1083, 1057, 1038, 1010, 964, 944, 880, 741, 697. HRMS (ESI-TOF, m/z) calculated 
for C28H40KO9
+
 ([M+K]
+
): 559.2304. Observed: 559.2322.  
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(R)-(2S,3R,E)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-1-
oxododec-6-en-3-yl 2-acetoxy-2-phenylacetate (R)-8h.  
 
(8.9 mg from 6.2 mg 7h, 98%). 
 
1
H NMR (400 MHz, CDCl3) δ 7.44 – 7.36 (m, 5H), 5.83 (s, 1H), 5.46 – 5.28 (m, 3H), 4.39 
(dd, J = 10.5, 4.2 Hz, 1H), 3.58 (dd, J = 11.8, 4.2 Hz, 1H), 3.51 (dd, J = 11.8, 10.5 Hz, 1H), 
3.36 (s, 3H), 3.27 – 3.18 (m, 4H), 2.17 (s, 3H), 2.09 – 1.85 (m, 4H), 1.79 (m, 1H), 1.65-1.50 
(m, 4H), 1.34-1.24 (m, 3H), 1.32 (s, 3H), 1.26 (s, 3H), 0.89 (t, J = 6.8 Hz, 3H), 0.77 (d, J = 
6.8 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 208.3, 170.3, 168.4, 133.6, 131.9, 129.3, 128.7, 
128.2, 127.7, 99.7, 98.0, 74.6, 74.0, 71.5, 59.7, 48.8, 48.0, 44.8, 32.7, 32.6, 31.4, 29.2, 28.5, 
22.5, 20.7, 17.8, 17.6, 14.0, 8.3. FTIR (thin film) νmax cm
-1
 2990, 2950, 2925, 2872, 2855, 
1743, 1716, 1497, 1456, 1373, 1333, 1297, 1261, 1230, 1209, 1175, 1141, 1115, 1083, 1054, 
1037, 1004, 968, 944, 879. HRMS (ESI-TOF, m/z) calculated for C31H46KO9
+
 ([M+K]
+
): 
601.2773. Observed: 601.2792. 
 
(S)-(2S,3R,E)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-1-
oxododec-6-en-3-yl 2-acetoxy-2-phenylacetate (S)-8h.  
 
(8.6 mg from 5.9 mg 7h, 100%). 
 
1
H NMR (300 MHz, CDCl3) δ 7.47 – 7.35 (m, 5H), 5.83 (s, 1H), 5.39 (ddd, J = 8.8, 4.5, 4.5 
Hz, 1H), 5.22 – 5.02 (m, 2H), 4.52 (dd, J = 11.0, 4.2 Hz, 1H), 3.73 (dd, J = 11.5, 4.2 Hz, 1H), 
3.61 (dd, J = 11.5, 11.0 Hz, 1H), 3.35 (s, 3H), 3.34 – 3.30 (m, 1H), 3.23 (s, 3H), 2.18 (s, 3H), 
1.90 – 1.81 (m, 2H), 1.66 – 1.08 (m, 10H), 1.34 (s, 3H), 1.28 (s, 3H), 1.06 (d, J = 6.9 Hz, 
3H), 0.88 (t, J = 6.9 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 208.7, 170.1, 168.4, 133.8, 
131.8, 129.2, 128.7, 128.0, 127.6, 99.7, 98.0, 74.5, 73.9, 71.9, 59.7, 48.7, 48.1, 45.2, 32.6, 
32.4, 31.4, 29.1, 28.1, 22.5, 20.7, 17.8, 17.6, 14.1, 9.5. FTIR (thin film) νmax cm
-1
 2989, 
2926, 2872, 2855, 1745, 1716, 1455, 1373, 1333, 1262, 1230, 1209, 1174, 1141, 1116, 1055, 
1037, 968, 945, 880. HRMS (ESI-TOF, m/z) calculated for C31H46KO9
+
 ([M+K]
+
): 
601.2773. Observed: 601.2797. 
 
(R)-(3R,4S,E)-5-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-4-methyl-5-oxo-
1-phenylpent-1-en-3-yl 2-acetoxy-2-phenylacetate (R)-8i.  
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(8.3 mg from 5.8 mg 7i, 97%). 
 
1
H NMR (400 MHz, CDCl3) δ 7.48 – 7.44 (m, 2H), 7.42 – 7.37 (m, 3H), 7.34 – 7.23 (m, 5H), 
6.53 (dd, J = 16.0, 1.2 Hz, 1H), 6.13 (dd, J = 16.0, 6.3 Hz, 1H), 5.92 (s, 1H), 5.90 (ddd, J = 
6.3, 5.9, 1.2 Hz, 1H), 4.30 (dd, J = 10.5, 4.5 Hz, 1H), 3.59 (dd, J = 11.5, 4.5 Hz, 1H), 3.54 
(dd, J = 11.4, 10.5 Hz, 1H), 3.44 – 3.37 (m, 1H), 3.29 (s, 3H), 3.20 (s, 3H), 2.18 (s, 3H), 1.35 
(s, 3H), 1.26 (s, 3H), 0.90 (d, J = 6.9 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 207.9, 170.3, 
168.0, 136.0, 133.6, 133.1, 129.3, 128.8, 128.6, 128.1, 127.6, 126.7, 124.7, 99.8, 98.1, 75.3, 
74.6, 72.1, 59.6, 48.7, 48.0, 46.0, 20.6, 17.8, 17.6, 9.9. FTIR (thin film) νmax cm
-1
 2991, 
2943, 2834, 1744, 1716, 1496, 1454, 1373, 1229, 1207, 1169, 1141, 1115, 1054, 1036, 1009, 
966, 943, 912, 879. HRMS (ESI-TOF, m/z) calculated for C30H40NO9
+
 ([M+NH4]
+
): 
558.2698. Observed: 558.2702.  
 
(S)-(3R,4S,E)-5-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-4-methyl-5-oxo-
1-phenylpent-1-en-3-yl 2-acetoxy-2-phenylacetate (S)-8i.  
 
(9.8 mg from 6.1 mg 7i, 98%). 
 
1
H NMR (400 MHz, CDCl3) δ 7.48 – 7.42 (m, 2H), 7.40 – 7.36 (m, 3H), 7.28 – 7.20 (m, 3H), 
7.13 (d, J = 6.7 Hz, 2H), 6.15 (d, J = 15.1 Hz, 1H), 5.98 – 5.88 (m, 3H), 4.44 (dd, J = 10.8, 
4.1 Hz, 1H), 3.72 (dd, J = 11.5, 4.1 Hz, 1H), 3.63 (dd, J = 11.5, 10.8 Hz, 1H), 3.53 – 3.45 (m, 
1H), 3.30 (s, 3H), 3.22 (s, 3H), 2.19 (s, 3H), 1.36 (s, 3H), 1.28 (s, 3H), 1.14 (d, J = 6.9 Hz, 
3H). 
13
C NMR (101 MHz, CDCl3) δ 208.3, 170.1, 167.9, 135.9, 133.7, 132.7, 129.3, 128.8, 
128.5, 128.0, 127.8, 126.5, 124.5, 99.9, 98.1, 75.2, 74.4, 72.3, 59.7, 48.6, 48.1, 46.0, 20.6, 
17.8, 17.6, 10.8. FTIR (thin film) νmax cm
-1
 2990, 2943, 2834, 1747, 1717, 1496, 1455, 1373, 
1332, 1230, 1207, 1172, 1142, 1116, 1055, 1036, 1011, 968, 944, 879. HRMS (ESI-TOF, 
m/z) calculated for C30H36KO9
+
 ([M+K]
+
): 579.1991. Observed: 579.2011. 
 
(R)-(2S,3R,E)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-1-
oxooct-4-en-3-yl 2-acetoxy-2-phenylacetate (R)-8j.  
 
(7.5 mg from 5.0 mg 7j, 98%). 
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1
H NMR (400 MHz, CDCl3) δ 7.45 – 7.35 (m, 5H), 5.87 (s, 1H), 5.72 – 5.63 (m, 2H), 5.41 
(dd, J = 15.5, 6.7 Hz, 1H), 4.28 (dd, J = 10.5, 4.4 Hz, 1H), 3.59 (dd, J = 11.5, 4.4 Hz, 1H), 
3.54 (dd, J = 11.5, 10.5 Hz, 1H), 3.32 (s, 3H), 3.31 – 3.24 (m, 1H), 3.21 (s, 3H), 2.17 (s, 3H), 
1.98 (dt, J = 7.0, 7.0, Hz, 2H), 1.39 – 1.34 (m, 2H), 1.33 (s, 3H), 1.26 (s, 3H), 0.92 – 0.80 (m, 
6H). 
13
C NMR (101 MHz, CDCl3) δ 208.1, 170.2, 167.9, 135.5, 133.8, 129.2, 128.7, 127.6, 
125.6, 99.8, 98.0, 75.5, 74.6, 71.9, 59.7, 48.7, 48.0, 46.0, 34.2, 22.0, 20.6, 17.8, 17.6, 13.5, 
9.8. FTIR (thin film) νmax cm
-1
 2991, 2956, 2930, 2873, 2835, 1745, 1716, 1497, 1456, 1373, 
1336, 1254, 1229, 1208, 1171, 1140, 1115, 1054, 1037, 1010, 967, 943, 879. HRMS (ESI-
TOF, m/z) calculated for C27H38KO9
+
 ([M+K]
+
): 545.2147. Observed: 545.2160.  
 
(S)-(2S,3R,E)-1-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-1-
oxooct-4-en-3-yl 2-acetoxy-2-phenylacetate (S)-8j.  
 
(7.3 mg from 5.3 mg 7j, 90%). 
 
1
H NMR (400 MHz, CDCl3) δ 7.44 – 7.33 (m, 5H), 5.87 (s, 1H), 5.67 (dd, J = 6.4, 6.4 Hz, 
1H), 5.39 (ddd, J = 14.8, 6.6, 6.6 Hz, 1H), 5.22 (dd, J = 14.8, 6.4 Hz, 1H), 4.40 (dd, J = 11.1, 
3.9 Hz, 1H), 3.71 (dd, J = 11.1, 3.9 Hz, 1H), 3.63 (dd, J = 11.1, 11.1 Hz, 1H), 3.43 – 3.35 (m, 
1H), 3.33 (s, 3H), 3.23 (s, 3H), 2.17 (s, 3H), 1.88 – 1.81 (dt, J = 7.0, 7.0 Hz, 2H), 1.35 (s, 
3H), 1.28 (s, 3H), 1.22 (m, 2H), 1.08 (d, J = 6.9 Hz, 3H), 0.76 (t, J = 7.3 Hz, 3H). 
13
C NMR 
(101 MHz, CDCl3) δ 208.5, 170.1, 167.9, 135.4, 133.7, 129.2, 128.7, 127.7, 125.2, 99.9, 
98.1, 75.6, 74.5, 72.2, 59.7, 48.6, 48.1, 45.8, 34.1, 21.9, 20.6, 17.8, 17.6, 13.4, 10.8. FTIR 
(thin film) νmax cm
-1
 3066, 2956, 1740 (shoulder), 1497, 1456, 1431, 1373, 1328, 1227 
(shoulder), 1170, 1141, 1114, 1082, 1048 (shoulder), 1004, 966, 944, 877. HRMS (ESI-TOF, 
m/z) calculated for C27H38KO9
+
 ([M+K]
+
): 545.2147. Observed: 545.2159.  
 
(1S,2S)-3-((2R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxan-2-yl)-2-methyl-3-oxo-1-
phenylpropyl acetate 10. 
 
Acetic anhydride (111 µL, 1.18 mmol, 2.0 equiv) was added dropwise to a stirring solution of 
the starting material 7a (200 mg, 0.592 mmol, 1 equiv) and N,N-4-dimethylaminopyridine 
(361 mg, 2.96 mmol, 5 equiv) in dichloromethane (5 mL) at 0 C under an atmosphere of dry 
argon. The mixture was stirred at this temperature for 15 min. Water (50 mL) and diethyl 
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ether (10 mL) were added and the mixture was stirred rapidly at room temperature for 2 min. 
The layers were separated and the aqueous layer was extracted thrice with diethyl ether (3 × 
10 mL). The combined organic layers were washed five times with saturated aqueous 
ammonium chloride (5 × 20 mL), water (10 mL) and brine (10 mL) and dried over 
magnesium sulfate. The solution was then filtered through a plug of silica gel (20 g, Merck 
9385 grade) which was washed several times with diethyl ether. The solvent was removed 
under reduced pressure to afford the product as a colourless oil (223 mg, 99%).  
 
1
H NMR (300 MHz, CDCl3) δ 7.36 – 7.23 (m, 5H), 6.35 (d, J = 5.3 Hz, 1H), 4.36 (dd, J = 
10.8, 4.2 Hz, 1H), 3.67-3.62 (m, 2H), 3.55 (dd, J = 11.5, 10.8 Hz, 1H), 3.33 (s, 3H), 3.23 (s, 
3H), 2.09 (s, 3H), 1.42 (s, 3H), 1.28 (s, 3H), 1.03 (d, J = 6.9 Hz, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ 209.0, 169.9, 139.0, 128.4, 127.9, 126.1, 99.9, 98.0, 74.3, 72.3, 59.5, 48.7, 48.1, 
47.7, 20.9, 17.8, 17.6, 10.0. FTIR (thin film) νmax cm
-1 
2990, 2947, 2834, 1740, 1715, 1495, 
1453, 1372, 1228, 1165, 1139, 1113, 1053, 1034, 1022, 969, 944, 878. HRMS (ESI-TOF, 
m/z) calculated for C20H28KO7
+
 ([M+K]
+
): 419.1467. Observed: 419.1484.  
 
(1S,2S,4R)-4,5-dihydroxy-2-methyl-3-oxo-1-phenylpentyl acetate 11.  
 
The starting material 10 (50.0 mg, 0.131 mmol) was dissolved in tetrahydrofuran (1 mL) and 
the solution was stirred at 0 C (water/ice bath). To this was added dropwise a mixture of 
trifluoroacetic acid (3 mL) and water (1 mL). The reaction was stirred at 0 C for 3 h. The 
reaction mixture was added portionwise to a stirring mixture of ice (10 g), saturated aqueous 
sodium bicarbonate (20 mL) and diethyl ether (20 mL). The mixture was extracted thrice 
with diethyl ether (3 × 20 mL). The combined organic layers were washed with brine and 
dried over magnesium sulfate. The solvent was removed under reduced pressure to afford the 
product as a viscous, colourless oil (33.1 mg, 95%).  
 
1
H NMR (400 MHz, MeOH) δ 7.36 – 7.23 (m, 5H), 6.20 (d, J = 6.8 Hz, 1H), 4.08 (dd, J = 
5.3, 4.0 Hz, 1H), 3.65 (dq, J = 6.8, 6.8 Hz, 1H), 3.55 (dd, J = 11.5, 4.0 Hz, 1H), 3.49 (dd, J = 
11.5, 5.3 Hz, 1H), 2.08 (s, 3H), 1.09 (d, J = 6.8 Hz, 3H). 
13
C NMR (101 MHz, MeOH) δ 
214.1, 171.8, 140.6, 129.4, 129.0, 127.7, 78.6, 76.3, 64.5, 48.9, 20.9, 11.7. FTIR (thin film) 
νmax cm
-1 
3447 (br), 3033, 2938, 2880, 1715 (has shoulder), 1496, 1455, 1373, 1231 (has 
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shoulder), 1117, 1050, 1021, 970, 916, 884, 761. HRMS (ESI-TOF, m/z) calculated for 
C14H18NaO5
+
 ([M+Na]
+
): 289.1052. Observed: 289.1054.  
 
(2S,3S)-3-acetoxy-2-methyl-3-phenylpropanoic acid 12.  
 
To a rapidly stirring mixture of the starting keto-diol 11 (50 mg, 0.188 mmol) in acetonitrile 
(3 mL), dichloromethane (3 mL) and water (3 mL) was added sodium periodate (400 mg, 
1.87 mmol, 9.9 equiv) at 0 C. The mixture was stirred at this temperature for 20 min. Water 
(10 mL) and diethyl ether (10 mL) were added and the mixture was stirred for 2 min. The 
layers were separated. The aqueous layer was extracted five times with diethyl ether (5 × 5 
mL). The combined organic layers were washed with brine (10 mL) and dried over 
magnesium sulfate. The solvent was removed under reduced pressure to afford the product as 
a paste (38.8 mg, 93%).  
 
1
H NMR (400 MHz, MeOH) δ 7.37 – 7.23 (m, 5H), 6.05 (d, J = 6.7 Hz, 1H), 2.94 (dq, J = 
6.9 Hz, 1H), 2.08 (s, 3H), 1.19 (d, J = 7.0 Hz, 3H). 
13
C NMR (101 MHz, MeOH) δ 176.7, 
171.7, 140.2, 129.4, 129.0, 127.7, 77.5, 46.8, 20.8, 12.8. FTIR (thin film) νmax cm
-1 
3032, 
2983, 2945, 1736, 1710, 1496, 1431, 1456, 1373, 1227, 1116, 1095, 1021, 973, 917, 847. 
HRMS (ESI-TOF, m/z) calculated for C12H14NaO4
+
 ([M+Na]
+
): 245.0790. Observed: 
245.0795.  
 
(2S,3S)-3-hydroxy-2-methyl-3-phenylpropanoic acid 13.  
 
To a solution of the starting acetate 12 (26.0 mg, 0.117 mmol, 1 equiv) in tetrahydrofuran (18 
mL) was added an aqueous solution of lithium hydroxide (0.1 M, 4.5 mL, 0.450 mmol, 3.85 
equiv) at room temperature. The mixture was stirred at room temperature overnight. Ether 
(20 mL) and dilute aqueous hydrochloric acid (1 M, 20 mL) were added and the mixture was 
stirred for 1 minute before separating the layers. The aqueous layer was extracted thrice with 
diethyl ether (3 × 20 mL). The combined organic layers were dried over magnesium sulfate. 
The solvent was removed under reduced pressure to afford the product as a white paste (18.6 
mg, 88%).  
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1
H NMR (300 MHz, CDCl3) δ 7.38 – 7.27 (m, 5H), 5.19 (d, J = 3.9 Hz, 1H), 2.84 (qd, J = 
7.2, 3.9 Hz, 1H), 1.15 (d, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3) δ 180.6, 141.0, 128.4, 
127.7, 125.9, 73.3, 46.1, 10.3. FTIR (thin film) νmax cm
-1 
3600-3000 (v. br), 3063, 3031, 
2983, 2924, 1704, 1494, 1454, 1402, 1196, 1122, 1060, 1021, 984, 909. HRMS (ESI-TOF, 
m/z) calculated for C10H12NaO3
+
 ([M+Na]
+
): 203.0679. Observed: 203.0676. []d = -22.0 (c 
= 0.9, CH2Cl2,  = -0.20, l = 10 cm).  
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